On July 13th, 2022
- FOTIVDA®(tivozanib), Clinical Webinar, August 25 at 5:30pm.
Efficacy, Safety, and Use for Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma (rrRCC) Following 2 or More Prior Systemic Therapies. Read More….
- A CMA bill to reduce prior authorization red tape has passed out of the Assembly Health Committee. Read More….
- California law prohibits prior authorization for biomarker testing, eff. July 1, 2022. Read More….
- A 4.42% proposed cut to the Medicare conversion factor for calendar year 2023, from $34.61 to $33.08, has been released by CMS. Read More….
- Health insurance companies and self-insured employer plans must disclose how much they pay for nearly every health care service. Read More….
To read the complete edition of The California Oncology Byte, click on the date below.